Brenipatide
TO CONFIRM
Research compound; name matches brenipatide (LY3537031), an investigational GIP and GLP-1 receptor agonist, with exact identity to be confirmed.
Evidence level. Little or no public data, or the exact identity is still being confirmed. About the badges
- Class
- TO CONFIRM
- Category
- Metabolic & Incretin
- Type
- Single compound
- Development and regulatory status
- Status not confirmed
What researchers study
Name matches brenipatide (LY3537031), an investigational Lilly GIP/GLP-1 receptor agonist listed in clinical trials for substance-use, psychiatric and obesity indications. Product identity and use case are to be confirmed by Novatide.
Research areas
- GIP and GLP-1 receptor signalling studies
- Substance-use disorder research listed in trial registries
- Specific use case to be confirmed by Novatide
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- registry listing
Public trial registries list brenipatide studies in alcohol use disorder, major depressive disorder, bipolar disorder, opioid use disorder and obesity
- literature check
Early clinical results are described in trade press but were not verified here
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
- Tirzepatiderelated GIP/GLP-1 receptor agonist for pharmacological comparison
- SemaglutideGLP-1 receptor agonist comparator
